Wiederhold Nathan P
Department of Pathology, Fungus Testing Laboratory, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX, 78229, USA.
Curr Infect Dis Rep. 2016 Dec;18(12):42. doi: 10.1007/s11908-016-0549-2.
The echinocandins are important agents for the treatment of invasive fungal infections, especially those caused by Candida species. However, as with other antimicrobial agents, microbiologic resistance to this class of antifungal agents has emerged and can result in clinical failure. Several studies have recently reported an increase in echinocandin resistance in Candida glabrata isolates at various medical centers in different geographic regions of the USA. Recent studies have also reported that many of these isolates may also be fluconazole resistant, leaving few treatment options available for clinicians to use in patients with invasive candidiasis caused by this species. Our understanding of the clinical relevance of specific point mutations within the FKS genes that cause echinocandin resistance and risk factors for the development of microbiologic resistance and clinical failure have also increased. The purpose of this review is to discuss echinocandin resistance in Candida species and recent reports that have increased our understanding of this growing clinical problem.
棘白菌素是治疗侵袭性真菌感染的重要药物,尤其是由念珠菌属引起的感染。然而,与其他抗菌药物一样,对这类抗真菌药物的微生物耐药性已经出现,并可能导致临床治疗失败。最近的几项研究报告称,在美国不同地理区域的多个医疗中心,光滑念珠菌分离株对棘白菌素的耐药性有所增加。最近的研究还报告说,许多这些分离株可能对氟康唑也耐药,这使得临床医生在治疗由该菌种引起的侵袭性念珠菌病患者时几乎没有可用的治疗选择。我们对导致棘白菌素耐药的FKS基因内特定点突变的临床相关性以及微生物耐药性和临床治疗失败发展的危险因素的理解也有所增加。本综述的目的是讨论念珠菌属中的棘白菌素耐药性以及最近的报告,这些报告增进了我们对这个日益严重的临床问题的理解。